Position in ARVN
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$132,802
-$1,772,065 QoQ
Shares Held
15,981
-92.9% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#125
of 198 holders
Holding Since
Sep 2021
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names. ARVN ranks #46 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ARVN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $132,802 | 15,981 | Shares | Sole | 2026-08-03 | |
| 2025-09-30 | $1,904,867 | 223,576 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $403,563 | 54,832 | Shares | Sole | 2025-08-07 | |
| 2024-06-30 | $1,284,974 | 48,271 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $1,660,116 | 40,216 | Shares | Sole | 2024-05-10 | |
| 2023-06-30 | $475,824 | 19,171 | Shares | Sole | 2023-08-11 | |
| 2022-03-31 | $242,280 | 3,600 | Shares | Sole | 2022-05-09 | |
| 2021-12-31 | $878,898 | 10,700 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $451,990 | 5,500 | Shares | Sole | 2021-11-10 | |
| No filing history on record for this holder in this stock. | ||||||